U.S. FDA advisory meetings through Aug 13

THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EDT/GMT.

For more information on the FDA's Advisory Committee meetings, see: here

ONCOLOGIC DRUGS ADVISORY COMMITTEE

DATE: July 15, 0800/1200

LOCATION: Hilton, 620 Perry Parkway, Gaithersburg, Md.

CONTACT: Nicole Vesely, 301-827-6793

The committee will discuss a new drug application from Johnson & Johnson (JNJ.N) for trabectedin intravenous infusion in combination with Doxil for the treatment of patients with relapsed ovarian cancer. The proposed trade name for trabectedin is Yondelis.

The committee also will discuss a supplemental new drug application from Johnson & Johnson for intravenous infusion of Doxil in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer who have received prior anthracycline treatment.